VIDEO: ctDNA shows high value in identifying patients at risk for developing lymphoma
Click Here to Manage Email Alerts
In this video, Stephen M. Ansell, MD, PhD, discusses research presented at ASH Annual Meeting and Exposition on circulating tumor DNA.
With circulating tumor DNA (ctDNA) “we’re seeing this being tested now in multiple places — in various histologies,” Ansell, professor of medicine in the department of hematology at Mayo Clinic, Minnesota, said.
In addition, he said ctDNA has shown a "clear benefit" in identifying patients at high risk for early relapse and as a predictive biomarker for patient outcome.
"We're going to see this now move to the next phase, which is can we actually act on it and change the outcomes of patients," Ansell said.
"Right now we can see who are patients who clearly are going to need more treatment. Will we be able to show that using more treatment in that circumstance actually changes patient outcome?" Ansell said.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts